TY - JOUR
T1 - Imaging biomarker validation and qualification report
T2 - Sixth oarsi workshop on imaging in osteoarthritis combined with third oa biomarkers workshop
AU - Hunter, D. J.
AU - Eckstein, F.
AU - Kraus, V. B.
AU - Losina, E.
AU - Sandell, L.
AU - Guermazi, A.
N1 - Funding Information:
Support for the meeting was provided by NIAMS Grant number: 5U13AR057296-03 . Support was also provided by the Arthritis Foundation , MERCK Serono , Sanofi , Fidia , Orthopedic Research Society , Pfizer , Bioclinica , Boston Imaging Core Lab , Novartis , Piramal Healthcare , QMetrics , Bioiberica , Bioventus , Chondrometrics , Optasia Medical and VirtualScopics .
Funding Information:
David J. Hunter is funded by an Australian Research Council Future Fellowship with support from the FNIH OA Biomarkers Consortium .
Funding Information:
Virginia Kraus is funded by grants from the Foundation for NIH, NIH/NIA Claude D Pepper 5P30 AG028716 and NIH/NIAMS 5P01-AR050245 .
Funding Information:
The authors wish to thank science writer Jeanne Erdmann for help in preparation of this manuscript. Ms Erdmann was supported by general funds for the meeting.
PY - 2013/7
Y1 - 2013/7
N2 - The sixth Osteoarthritis Research Society International (OARSI) Workshop on Imaging in Osteoarthritis combined with the third osteoarthritis (OA) Biomarkers Workshop is the first to bring together the imaging and molecular biomarker communities to focus on clinical validation and qualification of OA biomarkers. The workshop was held in Hilton Head, SC, USA, from June 12-14, 2012; 138 attendees participated, including representatives from academia, pharmaceutical and magnetic resonance imaging (MRI) industries, Food and Drug Administration (FDA), and National Institutes of Health (NIH). Presentations and discussions raised awareness, consolidated knowledge, and identified strategies to overcome challenges for the development and application of imaging and biochemical biomarkers in OA research studies and clinical trials. Conclusion: The OA research communities need to work alongside regulatory agencies across the world, to qualify and validate new chemical and imaging biomarkers for future research and clinical trials.
AB - The sixth Osteoarthritis Research Society International (OARSI) Workshop on Imaging in Osteoarthritis combined with the third osteoarthritis (OA) Biomarkers Workshop is the first to bring together the imaging and molecular biomarker communities to focus on clinical validation and qualification of OA biomarkers. The workshop was held in Hilton Head, SC, USA, from June 12-14, 2012; 138 attendees participated, including representatives from academia, pharmaceutical and magnetic resonance imaging (MRI) industries, Food and Drug Administration (FDA), and National Institutes of Health (NIH). Presentations and discussions raised awareness, consolidated knowledge, and identified strategies to overcome challenges for the development and application of imaging and biochemical biomarkers in OA research studies and clinical trials. Conclusion: The OA research communities need to work alongside regulatory agencies across the world, to qualify and validate new chemical and imaging biomarkers for future research and clinical trials.
KW - Imaging workshop
KW - Osteoarthritis
UR - http://www.scopus.com/inward/record.url?scp=84879459925&partnerID=8YFLogxK
U2 - 10.1016/j.joca.2013.04.014
DO - 10.1016/j.joca.2013.04.014
M3 - Article
C2 - 23639411
AN - SCOPUS:84879459925
SN - 1063-4584
VL - 21
SP - 939
EP - 942
JO - Osteoarthritis and Cartilage
JF - Osteoarthritis and Cartilage
IS - 7
ER -